Intriguingly, although CS patients do not tend to develop cancer, mouse models with CSB mutations do show an elevated cancer incidence [38], suggesting that in some contexts, TCR loss can be oncogenic, but in humans, the syndrome’s lethal developmental effects manifest before cancer can arise. This evidence concerns the gene ERCC6 and Cowden syndrome 1.